Pancreatic Cancer Research

ResearcherUniversity of Electronic Science and Technology of ChinaActive in the last 2 years

Yi Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-0864-2989; OpenAlex author ID A5100421377. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. Pi Ji Pills reshape the pancreatic cancer immune microenvironment and enhance the efficacy of gemcitabine through dual mechanisms of PI3K/AKT pathway blockade … Co-author DOI 10.1016/j.jep.2025.120579↗
  2. Current and projected incidence rates of pancreatic cancer in 43 countries: an analysis of the Cancer Incidence in Five Continents database. Co-author DOI 10.1136/bmjgast-2024-001544↗
  3. A commentary on 'Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer'. First author DOI 10.1097/js9.0000000000001568↗
  4. Combined Efficacy of Nimotuzumab and Gemcitabine on the Treatment of Advanced Pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000002328↗
  5. SDC1 and ITGA2 as novel prognostic biomarkers for PDAC related to IPMN. Co-author DOI 10.1038/s41598-023-44646-x↗
  6. Pan-cancer analysis and experimental validation identify ndc1 as a potential immunological, prognostic and therapeutic biomarker in pancreatic cancer. Co-author DOI 10.18632/aging.205048↗
  7. An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms. Co-author DOI 10.1038/s41467-022-33037-x↗
  8. Discovering a Four-Gene Prognostic Model Based on Single-Cell Data and Gene Expression Data of Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fendo.2022.883548↗
  9. DBDx-based drug combinations show highly potent therapeutic efficacy against human pancreatic cancer xenografts in athymic mice. Co-author DOI 10.1080/15384047.2020.1776580↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bo Pang · 4 shared papers, 2023–2026 · strength 0.93
  2. Qian Shen · 3 shared papers, 2023–2026 · strength 0.70
  3. Chuanlong Zhang · 3 shared papers, 2023–2026 · strength 0.70
  4. Changyuan Wang · 1 shared paper, 2024 · strength 0.36
  5. Bole Tian · 1 shared paper, 2024 · strength 0.36
  6. Jun Li · 1 shared paper, 2024 · strength 0.31
  7. Baojin Hua · 1 shared paper, 2025 · strength 0.23
  8. Songting Shou · 1 shared paper, 2025 · strength 0.23
  9. Xing Zhang · 1 shared paper, 2025 · strength 0.23
  10. Weizhen Huang · 1 shared paper, 2022 · strength 0.20
  11. Xia Yuan · 1 shared paper, 2022 · strength 0.20
  12. Yanbo Zheng · 1 shared paper, 2020 · strength 0.15
  13. Yong‐Su Zhen · 1 shared paper, 2020 · strength 0.15
  14. Hong-Juan Yao · 1 shared paper, 2022 · strength 0.13
  15. Yuchen Shi · 1 shared paper, 2022 · strength 0.13
  16. Rong‐Guang Shao · 1 shared paper, 2022 · strength 0.13
  17. Rui Cao · 1 shared paper, 2022 · strength 0.13
  18. Xiaofei Zhou · 1 shared paper, 2022 · strength 0.13
  19. Liang Li · 1 shared paper, 2022 · strength 0.13
  20. Hebing Chen · 1 shared paper, 2022 · strength 0.13
  21. Li Zhang · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.